InvestorsHub Logo

blackhawks

01/21/24 7:43 PM

#1922 RE: a surfer #1912

Of COURSE you'd run, you're an ill-informed nut job. There are different risks for Covid among the immunocompromised and the elderly, so your narrow junk science fueled view of matters counts for 💩

https://pubmed.ncbi.nlm.nih.gov/35306713/#:~:text=Cutaneous%20vasculitis%20is%20a%20rare,after%20first%20or%20second%20shot.

Cutaneous vasculitis is a rare adverse event to COVID-19 vaccination. It has been observed with mRNA and adenovirus-vector vaccines. IgA vasculitis, lymphocytic and ANCA-associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot.

Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID-vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.